DB107-FC

Phase 2Small molecule

UUniversity of California, San Francisco

DB107-FC is one of 62 small molecule programs targeting Anaplastic Astrocytoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anaplastic AstrocytomaRecruiting

GliomaRecruiting

Anaplastic AstrocytomaPhase 2

Recruiting

GliomaPhase 2

Recruiting

Competition

Competitive Landscape

103 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

23 2

Paraplatin

AAvyxa

Phase 3

13 3

Voranigo

SServier

Phase 3

5 4

Ojemda

Day One Biopharmaceuticals

Phase 3

3 5

Opdivo

Bristol-Myers Squibb

Phase 2

13 6

Keytruda

Merck & Co.

Phase 2

5 7

Camptosar

Pfizer

Phase 2

5 8

Lynparza

AstraZeneca

Phase 2

3 9

Verzenio

Eli Lilly

Phase 2

3 10

Dostarlimab

Incyte

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2034

Phase 2Recruiting

Anaplastic Astrocytoma

NCT06264388

Q1 2042

Phase 1/2Recruiting

Glioma

NCT06504381

Clinical

Trials by Indication[1]

Anaplastic Astrocytoma1 trial

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma

Recruiting·AAshish Shah·Phase 2·NCT06264388·33 enrolled

Glioma1 trial

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

Recruiting·UUniversity of California, San Francisco·Phase 1/2·NCT06504381·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for DB107-FC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DB107-FC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DB107-FC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of California, San Francisco

DB107-FC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2034

Q1 2042

Trials by Indication[1]

Anaplastic Astrocytoma1 trial

Glioma1 trial

References

Drug Info

Quick Facts

Related News